Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the United States market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the United States in a variety of low-cost generic formulations . 
Dr. Mulholland and SpaMedica have been at the forefront of non-surgical liposuction and fat reduction technologies, often pioneering these treatments. Dr. Mulholland has spoken nationally and internationally on the use of high-frequency focused ultrasound, such as Liposonix and UltraShape for the permanent reduction of fat. By selecting SpaMedica and Dr. Mulholland, you will be attending a centre with one of the world’s most experienced practitioners at the helm of the treatment of the program. In general, at SpaMedica, you receive more than one permanent reduction technology to optimize your non-surgical liposuction fat reduction results. Dr. Mulholland will ensure that you also get skin tightening devices at the same time as fat reduction to help you achieve the best possible fat reduction with the most advanced technology available. In addition, Toronto non-surgical liposuction fat reduction patients that attend SpaMedica are able to one day apply a significant proportion of their non-surgical liposuction fees against a minimally-invasive BodyTite or SmartLipo liposuction procedure to improve even more upon their permanent focal contour reduction goals.